Bevacizumab plus chemotherapy versus combination chemotherapy only in metastatic, recurrent, and persistent cervical cancer

被引：0
|
作者：
Choi, H. [1 ]
Kim, B. G. [2 ]
Lee, Y. Y. [3 ]
机构：
[1] Chung Ang Univ, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Seoul, South Korea
[3] Samsung Med Ctr, Seoul, South Korea
来源：
GYNECOLOGIC ONCOLOGY | 2019年 / 154卷
关键词：
D O I：
10.1016/j.ygyno.2019.04.642
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2537
引用
收藏
页码：275 / 275
页数：1
相关论文
共 50 条
  • [1] Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer
    Choi, Hyun-Jin
    Lee, Yoo-Young
    Choi, Chel Hun
    Kim, Tae-Joong
    Lee, Jeong-Won
    Bae, Ji Hye
    Bae, Duk-Soo
    Kim, Byoung-Gie
    [J]. CURRENT PROBLEMS IN CANCER, 2020, 44 (05)
  • [2] Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
    McNamara, Blair
    Chang, Yifan
    Mutlu, Levent
    Harold, Justin
    Santin, Alessandro D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (03) : 227 - 233
  • [3] KEYNOTE-826: PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K.
    Salman, P.
    Usta, E. Hoyos
    Yanez, E.
    Gumus, M.
    de Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S.
    Monk, B.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A364 - A364
  • [4] Chemotherapy in recurrent and metastatic cervical cancer: single agent versus combination chemotherapy
    Kumar, L
    Pokharel, YH
    Kumar, S
    Singh, R
    Rath, GK
    Kochupillai, V
    [J]. 17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 1225 - 1228
  • [5] Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer
    Eskander, Ramez N.
    Tewari, Krishnansu S.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (04) : 314 - 321
  • [6] EFFICACY AND SAFETY OF BEVACIZUMAB COMBINATION CHEMOTHERAPY FOR RECURRENT CERVICAL CANCER
    Kusakabe, M.
    Tanikawa, M.
    Oda, K.
    Nagasaka, K.
    Miyamoto, Y.
    Sone, K.
    Mori, M.
    Tsuruga, T.
    Matsumoto, Y.
    Osuga, Y.
    Fujii, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 318 - 318
  • [7] Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review
    Hirte, H. W.
    Strychowskyz, J. E.
    Oliverz, T.
    Fung-Kee-Fung, M.
    Elit, L.
    Oza, A. M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (06) : 1194 - 1204
  • [8] The efficacy and safety of addition of bevacizumab to combination chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Single institute experiences in Korea
    Lee, Y. J.
    Kim, Y. M.
    Mok, J. E.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 391 - 391
  • [9] Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
    Li, Zhigui
    Huang, Yuqian
    Zhao, Rui
    Cui, Yaping
    Zhou, Yong
    Wu, Xiaoting
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [10] Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
    Zhigui Li
    Yuqian Huang
    Rui Zhao
    Yaping Cui
    Yong Zhou
    Xiaoting Wu
    [J]. Scientific Reports, 8
12345